Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
Status:
Recruiting
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
This study will enroll patients who received neoadjuvant therapy for TNBC prior to surgery
and did not get pCR. Given the relatively poor prognosis for these patients, this population
is considered novel therapeutic as adjuvant treatment. Currently, capecitabine monotherapy
could be beneficial to this group of patients according to CREATE-X trial results. The
investigators are addressing the effect of anti-PD-L1, atezolizumab combined with
capecitabine in patients with TNBC who did not get pCR after neoadjuvant chemotherapy
compared to capecitabine monotherapy.